impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Diagnosis

 

Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16

 

  1. Department of Rheumatology, St. Vincent’s Hospital Melbourne, Victoria, Australia, and Department of Rheumatology, Derriford Hospital, Plymouth, Devon, UK.
  2. Rheumatology Unit, Royal Adelaide Hospital; and Discipline of Medicine, University of Adelaide, South Australia.
  3. Department of Respiratory Medicine, Austin Hospital Melbourne, Victoria; and Department of Respiratory Medicine, Alfred Hospital Melbourne, Victoria, Australia.
  4. Department of Respiratory Medicine, Royal Prince Alfred Hospital Sydney, New South Wales, Australia.
  5. Department of Radiology, St. Vincent’s Hospital Melbourne, Victoria, Australia.
  6. Department of Radiology, St. Vincent’s Hospital Melbourne, Victoria, Australia.
  7. Department of Rheumatology, St. Vincent’s Hospital Melbourne, Victoria, Australia.
  8. Department of Rheumatology, St. Vincent’s Hospital Melbourne, Victoria; and Department of Rheumatology, Liverpool Hospital Sydney; and School of Medicine, University of Western Sydney, New South Wales, Australia.
  9. Department of Rheumatology, Monash Medical Centre Melbourne, Victoria, Australia.
  10. Department of Rheumatology, Royal Perth Hospital, Western Australia.
  11. Department of Rheumatology, Royal Prince Alfred Hospital and Sydney University, New South Wales, Australia.
  12. Advanced Lung Disease Unit, Royal Perth Hospital; and The University of Notre Dame, Fremantle, Western Australia.
  13. Rheumatology Research Unit, Department of Medicine, University of Queensland, QLD, Australia.
  14. The Menzies Research Institute, Tasmania.
  15. Department of Rheumatology, St. Vincent’s Hospital Melbourne, Victoria, Australia.
  16. Department of Rheumatology, St. Vincent’s Hospital Melbourne, Victoria; and The University of Melbourne Department of Medicine, St. Vincent’s Hospital Melbourne, Victoria, Australia. m.nikpour@unimelb.edu.au

CER8009
2015 Vol.33, N°4 ,Suppl.91
PI 0111, PF 0116
Diagnosis

Free to view
(click on article PDF icon to read the article)

PMID: 26243401 [PubMed]

Received: 07/10/2014
Accepted : 23/04/2015
In Press: 05/08/2015
Published: 31/08/2015

Abstract

OBJECTIVES:
Clinically meaningful change in systemic sclerosis (SSc) related interstitial lung (SSc-ILD) disease is unknown. The aim of this study was to quantify change in pulmonary function as a predictor of outcome in SSc-ILD.
METHODS:
All patients had SSc-ILD defined by HRCT chest. All PFTs during follow-up, including FVC (L), DLCO (ml/min/mmHg) and KCO (DLCO/alveolar volume ratio; DLCO/VA) (ml/min/mmHg/L) were retrieved. The rate of change over the first four years, and percentage change in the first year of follow-up were used in ROC curve analysis to determine the best cut-off points to predict adverse outcome (home oxygen, lung transplantation, or death).
RESULTS:
Among 264 patients, there were 49 events (38 deaths, 10 supplemental oxygen, one lung transplant) over a mean (±SD) follow-up of 3.0 (±1.7) years. The rates of decline over time and percentage change over one year in each of FVC, DLCO and KCO were predictive of adverse outcome. Stable PFTs over four years gave the optimal negative predictive values (NPVs) of 88–96%. The best sensitivity-specificity trade-off was a decline in FVC of 10% and in DLCO and KCO of 15% with NPVs of 92–93%.
CONCLUSIONS:
The course that SSc-ILD takes is evident within the first 1–4 years of follow up. Patients who have no decline in PFTs over 4 years have better outcomes. A decline within one year in DLCO or KCO of 15% or more is a poor prognostic factor, and identifies patients who should be monitored more closely and considered for therapy.

Rheumatology Article